Loehrer Elizabeth, Wagner Anja, Bahar Massiah, Ramzan F Rubab, Jelsig Anne Marie, Goverde Anne, van Leerdam Monique, Korsse Susanne E, Dekker Evelien, Spaander Manon C W, Karstensen John Gásdal, Zuber Veronica, Macrae Finlay, Latchford Andrew
Department of Clinical Genetics, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
St Mark's Hospital, Harrow, UK.
Fam Cancer. 2025 May 3;24(2):41. doi: 10.1007/s10689-025-00469-5.
Female patients with Peutz-Jeghers syndrome (PJS) have an increased risk of breast cancer (BrCa), and surveillance is recommended. However, clinicopathological features of their tumors and prognosis are lacking. To facilitate more precise future guideline development, we evaluated these data.
We conducted an international survey for InSiGHT members to collect retrospective data on PJS patients with diagnosed breast cancer.
We received 23 responses, including three centers with data on BrCa patients. All reported BrCa patients were female. In total, the cohort comprised 27 patients with 34 BrCa (five bilateral synchronous, one bilateral metachronous, and one metachronous unilateral tumours). The median age at first cancer diagnosis was 45 years (range 26-67). Most cancers were ductal carcinoma, either invasive (13) or in situ (DCIS; 19). TNM staging for invasive cancer was available in thirteen cases, of which nine were T1N0M0. Among tumors with histological reports, 14/15 were oestrogen receptor positive, 8/15 were progesterone receptor positive, and 4/15 were HER2 positive. There were no triple negative breast cancers. Twenty-five patients had follow-up data, comprising 229 patient years. Eleven patients had died of any cause during follow-up. Survival at 5 years was 73%.
Overall, breast cancers that occur in this PJS population seem to have favorable characteristics and prognosis. These data will help inform discussions about risk management in patients with PJS. Further research is needed to better understand lifetime risk, the optimal surveillance modality and its outcomes.
患有黑斑息肉综合征(PJS)的女性患者患乳腺癌(BrCa)的风险增加,建议进行监测。然而,关于其肿瘤的临床病理特征和预后的数据尚缺乏。为了便于制定更精确的未来指南,我们评估了这些数据。
我们对国际胃肠道间质瘤研究组(InSiGHT)成员进行了一项调查,以收集已确诊患有乳腺癌的PJS患者的回顾性数据。
我们收到了23份回复,其中包括三个提供乳腺癌患者数据的中心。所有报告的乳腺癌患者均为女性。该队列总共包括27例患者,共34例乳腺癌(5例双侧同步,1例双侧异时,1例异时单侧肿瘤)。首次癌症诊断时的中位年龄为45岁(范围26 - 67岁)。大多数癌症为导管癌,包括浸润性(13例)或原位癌(导管原位癌;19例)。13例浸润性癌有TNM分期数据,其中9例为T1N0M0。在有组织学报告的肿瘤中,14/15为雌激素受体阳性,8/15为孕激素受体阳性,4/15为HER2阳性。没有三阴性乳腺癌。25例患者有随访数据,共229患者年。11例患者在随访期间因任何原因死亡。5年生存率为73%。
总体而言,PJS人群中发生的乳腺癌似乎具有良好的特征和预后。这些数据将有助于为PJS患者的风险管理讨论提供信息。需要进一步研究以更好地了解终生风险、最佳监测方式及其结果。